Clinical Trial Update: The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ranibizumab plus transpupillary thermotherapy for neovascular age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Ranibizumab (Lucentis) (ranibizumab)

Snippet

Sponsor: Anders Kvanta | Conditions: Neovascular Age-related Macular Degeneration | Phase 3 | Status: COMPLETED